473 related articles for article (PubMed ID: 32999455)
21. Chimeric Antigen Receptor T Cell Immunotherapy for Tumor: A Review of Patent Literatures.
Fu M; Tang L
Recent Pat Anticancer Drug Discov; 2019; 14(1):60-69. PubMed ID: 30636615
[TBL] [Abstract][Full Text] [Related]
22. Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.
Kim MG; Kim D; Suh SK; Park Z; Choi MJ; Oh YK
Arch Pharm Res; 2016 Apr; 39(4):437-452. PubMed ID: 26895243
[TBL] [Abstract][Full Text] [Related]
23. CAR-T cells: the Chinese experience.
Wang L; Tan Su Yin E; Zhao H; Ni F; Hu Y; Huang H
Expert Opin Biol Ther; 2020 Nov; 20(11):1293-1308. PubMed ID: 32605454
[TBL] [Abstract][Full Text] [Related]
24. Revving the CAR - Combination strategies to enhance CAR T cell effectiveness.
Bansal R; Reshef R
Blood Rev; 2021 Jan; 45():100695. PubMed ID: 32402724
[TBL] [Abstract][Full Text] [Related]
25. Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.
Lin C; Zhang J
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):200-215. PubMed ID: 29378229
[TBL] [Abstract][Full Text] [Related]
26. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
Yu S; Yi M; Qin S; Wu K
Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
[TBL] [Abstract][Full Text] [Related]
27. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges.
Han EQ; Li XL; Wang CR; Li TF; Han SY
J Hematol Oncol; 2013 Jul; 6():47. PubMed ID: 23829929
[TBL] [Abstract][Full Text] [Related]
28. Target selection for CAR-T therapy.
Wei J; Han X; Bo J; Han W
J Hematol Oncol; 2019 Jun; 12(1):62. PubMed ID: 31221182
[TBL] [Abstract][Full Text] [Related]
29. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
30. Chimeric antigen receptor T cell therapy in oncology - Pipeline at a glance: Analysis of the ClinicalTrials.gov database.
Moreno-Cortes E; Forero-Forero JV; Lengerke-Diaz PA; Castro JE
Crit Rev Oncol Hematol; 2021 Mar; 159():103239. PubMed ID: 33497760
[TBL] [Abstract][Full Text] [Related]
31. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
32. CAR T cell immunotherapy for human cancer.
June CH; O'Connor RS; Kawalekar OU; Ghassemi S; Milone MC
Science; 2018 Mar; 359(6382):1361-1365. PubMed ID: 29567707
[TBL] [Abstract][Full Text] [Related]
33. Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy.
Stoiber S; Cadilha BL; Benmebarek MR; Lesch S; Endres S; Kobold S
Cells; 2019 May; 8(5):. PubMed ID: 31108883
[TBL] [Abstract][Full Text] [Related]
34. [Prospect for chimeric antigen receptor-engineered T cell immunotherapy for solid tumors].
Zhou SY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):490-492. PubMed ID: 30060355
[TBL] [Abstract][Full Text] [Related]
35. CARTs for Solid Tumors: Feasible or Infeasible?
Li W; Song X; Jin Y; Li F; Yu H; Cao C; Jiang Q
Oncol Res Treat; 2017; 40(9):540-546. PubMed ID: 28813706
[TBL] [Abstract][Full Text] [Related]
36. CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy.
Rotolo R; Leuci V; Donini C; Cykowska A; Gammaitoni L; Medico G; Valabrega G; Aglietta M; Sangiolo D
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31212634
[TBL] [Abstract][Full Text] [Related]
37. CAR T-Cell Therapy in Hematological Malignancies.
Haslauer T; Greil R; Zaborsky N; Geisberger R
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
[TBL] [Abstract][Full Text] [Related]
38. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
39. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
Qu J; Mei Q; Chen L; Zhou J
Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
[TBL] [Abstract][Full Text] [Related]
40. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.
Li J; Li W; Huang K; Zhang Y; Kupfer G; Zhao Q
J Hematol Oncol; 2018 Feb; 11(1):22. PubMed ID: 29433552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
